Measurement of ERK 1/2 in CSF from patients with neuropsychiatric disorders and evidence for the presence of the activated form.

Détails

ID Serval
serval:BIB_03F04FC77E20
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Measurement of ERK 1/2 in CSF from patients with neuropsychiatric disorders and evidence for the presence of the activated form.
Périodique
Journal of Alzheimer's Disease : Jad
Auteur⸱e⸱s
Klafki H.W., Lewczuk P., Kamrowski-Kruck H., Maler J.M., Müller K., Peters O., Heuser I., Jessen F., Popp J., Frölich L., Wolf S., Prinz B., Luckhaus C., Schröder J., Pantel J., Gertz H.J., Kölsch H., Müller B.W., Esselmann H., Bibl M., Kornhuber J., Wiltfang J.
ISSN
1875-8908 (Electronic)
ISSN-L
1387-2877
Statut éditorial
Publié
Date de publication
2009
Peer-reviewed
Oui
Volume
18
Numéro
3
Pages
613-622
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov'tPublication Status: ppublish
Résumé
The clinical diagnosis of neurodegenerative disorders can be supported by soluble biomarkers in cerebrospinal fluid (CSF), such as tau protein, phospho-tau, and amyloid-beta peptides. In particular, increased CSF levels of phospho-tau in Alzheimer's disease appear to reflect disease specific pathological processes. We report here evidence for the presence of soluble MAP-kinase ERK1/2 in a small set of human CSF samples from patients with Alzheimer's disease, frontotemporal degeneration, and mild cognitive impairment. The level of total ERK1/2 in CSF as measured by electrochemiluminescent assay was correlated with that of total tau and phospho-tau. A small fraction of ERK1/2 in a pooled CSF sample was found to be in the doubly phosphorylated (activated) state. Our findings suggest that i) MAP kinase ERK1/2 is apparently released under neurodegenerative conditions in parallel with tau and phospho-tau and ii) in the future, it might be possible to find in CSF samples evidence for disease related alterations in brain kinase signaling pathways by use of highly sensitive and activation-state specific anti-kinase antibodies.
Mots-clé
Aged, Alzheimer Disease/cerebrospinal fluid, Alzheimer Disease/genetics, Antibodies, Monoclonal, Blotting, Western, Extracellular Signal-Regulated MAP Kinases/cerebrospinal fluid, Extracellular Signal-Regulated MAP Kinases/genetics, Female, Frontotemporal Lobar Degeneration/cerebrospinal fluid, Frontotemporal Lobar Degeneration/genetics, Humans, Immunoprecipitation, Male, Mitogen-Activated Protein Kinase 3/cerebrospinal fluid, Mitogen-Activated Protein Kinase 3/genetics, Severity of Illness Index, tau Proteins/cerebrospinal fluid, tau Proteins/genetics
Pubmed
Création de la notice
29/10/2012 10:58
Dernière modification de la notice
20/08/2019 12:25
Données d'usage